49.69 +0.63 (1.28%)
After hours: 6:07PM EST
|Bid||47.28 x 900|
|Ask||49.75 x 1000|
|Day's Range||48.40 - 49.72|
|52 Week Range||10.41 - 51.84|
|Beta (3Y Monthly)||1.67|
|PE Ratio (TTM)||102.00|
|Earnings Date||Nov 25, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||45.71|
Arrowhead Pharmaceuticals, Inc. (ARWR) today announced that Bruce Given, M.D., Arrowhead’s chief operating officer and head of R&D, plans to retire on May 1, 2020, after a more than 30 year career in biotechnology and pharmaceutical research, development, and sales and marketing. Arrowhead also announced the hiring of Javier San Martin, M.D., in the role of chief medical officer, and Curt Bradshaw, Ph.D., in the role of chief scientific officer, both effective on Monday, November 18, 2019. During the next six months, Dr. Given will work closely with Dr. San Martin and Dr. Bradshaw to ensure a smooth transition and will also be retained in an advisory capacity for a period of at least one year following his retirement.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a webcast and conference call on November 25, 2019, at 4:30 p.m. EST to discuss its financial results for the fiscal year ended September 30, 2019. For analysts that wish to participate in the conference call, please dial 855-215-6159 or 315-625-6887 and provide Conference ID 7768049. To access the audio replay, dial 855-859-2056 or 404-537-3406 and provide Conference ID 7768049.
Arrowhead Pharmaceuticals and Johnson & Johnson said Friday they eradicated nearly all traces of hepatitis B virus in a study — sending Arrowhead careening toward another record high.
Arrowhead Pharmaceuticals Inc. today announced Phase 2 clinical data on a double combination of JNJ-3989 and a nucleos ide analog , and the first clinical data on a triple combination of JNJ-3989, JNJ-6379, and an NA, with collaborator Janssen Pharmaceuticals, Inc., part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
Arrowhead Pharmaceuticals Inc. (ARWR) today presented preclinical data at the 2019 North American Cystic Fibrosis Conference (NACFC) on ARO-ENaC, an inhaled RNAi therapeutic being developed as a potential treatment for cystic fibrosis (CF), which is a rare disease caused by genetic mutations that lead to mucus buildup in the lungs and pancreas. Arrowhead is currently conducting IND/CTA-enabling studies to support regulatory filings in the first half of 2020 for first-in-human studies. Bruce Given, M.D., chief operating officer and head of R&D at Arrowhead, said: “We view the epithelial sodium channel, ENaC, as an exciting target in the treatment of CF and one that is well suited to an RNAi-based intervention.
One of the leading Cambridge biotechs hoping to treat diseases by silencing the genetic causes could get as much as $1.67 billion to develop a treatment for hepatitis B.
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many...
Is Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research on a given stock. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after […]
Arrowhead Pharma stock flirted with a breakout Friday after the biotech company said it's experimenting with silencing multiple genes as well as moving into diseases outside the liver.
For his "Executive Decision" segment of Mad Money Thursday night, Jim Cramer spoke with Christopher Anzalone, president and CEO of Arrowhead Pharmaceuticals , the development-stage biotech focusing on gene therapy. Anzalone explained that Arrowhead is pioneering gene therapies developed around the concept of RNA interference, which acts to silence, or turn off, certain genes that are known to cause disease. Arrowhead currently has big name partnerships with Johnson & Johnson and Amgen to help them develop and commercialize various drugs based off of the company's technology.
Arrowhead Pharmaceuticals, Inc. is hosting a Research & Development Day today in New York to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule Platform platform.
Medical stocks dominate today’s top charts to watch. AbbVie Inc. (ABBV) climbed $1.72 to $73.85 on 6.2 million shares traded Thursday. Arrowhead Pharmaceuticals Inc. (ARWR) jumped $1 to $29.92 on 883,800 shares traded Thursday.
Arrowhead Pharmaceuticals Inc. (ARWR) today announced that it will host a Research & Development (R&D) Day to discuss its emerging pipeline of RNAi therapeutics that leverage its proprietary Targeted RNAi Molecule (TRIMTM) platform from 8:30 a.m. to 11:30 a.m. EDT on October 18, 2019, in New York City. The meeting will feature a presentation by Ira Goldberg, M.D. (NYU Langone Medical Center), who will discuss the current treatment landscape and unmet medical need for patients with dyslipidemia and hypertriglyceridemia.
Arrowhead Pharmaceuticals Inc. today announced that it is scheduled to participate in the following upcoming events:
By Brian Marckx, CFA NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT Pipeline Highlights: APOC3/ANG3 Topline Data, Orphan Desig. JNJ-3989 in Ph2b, Cohort 12 Data Upcoming. And More … Arrowhead (NASDAQ:ARWR) continues to make rapid progress across most of their pipeline. There has been no shortage of positive product development related events as
Chris Anzalone became the CEO of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) in 2007. First, this article will...